- SciSparc ( NASDAQ: SPRC ) said it received approval from Soroka University Medical Center to conduct its clinical study for SCI-210 in patients with autism spectrum disorder (ASD).
- During 2022, SciSparc had received approvals from the Israeli Ministry of Health and the Ethics Committee of Soroka to conduct the trial, the company added.
- On Jan. 9, SciSparc had announced that it signed an agreement with Soroka to perform its study, led by Gal Meiri, head of Soroka Medical Center's Preschool Psychiatry Unit.
- The trial will evaluate SCI-210, a proprietary combination of cannabidiol (CBD) and CannAmide, in comparison to CBD monotherapy to treat children with ASD.
- ASD is a condition related to brain development which impacts how a person perceives and socializes.
- SPRC +5.61% to $1.13 premarket Jan. 18
For further details see:
SciSparc stock rises on getting approval in Israel to conduct trial of SCI-210 for autism